Stroke Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 to 85 years (up to but not including their 86th birthday) who have been diagnosed with an acute ischemic stroke (a stroke caused by a blockage)
- People whose stroke symptoms score at least 6 on a standard medical severity scale (NIHSS), indicating a moderate to severe stroke
- People who are between 24 and 72 hours past the time they were last known to be well before their stroke was noticed
- People who were fully independent or had only very minor disability before their stroke (pre-stroke modified Rankin Scale score of 0–1)
- People who are considered suitable for both a clot-removal procedure (thrombectomy) and standard medical treatment
- People who have signed a consent form agreeing to participate
- People who are willing to attend all required follow-up visits as set out in the study plan
- People who are expected to live for at least 3 months
- People whose brain scans show a blockage in one of the large blood vessels supplying the brain (the internal carotid artery or the main middle cerebral artery), confirmed by specialised scan imaging (MRA or CTA)
- People whose brain scan score (CT ASPECTS) falls between 3 and 10, indicating that not too much brain tissue has already been damaged
- People whose brain scans show that the area of severely damaged brain tissue is 150 ml or less in volume, measured using specific perfusion or diffusion imaging methods
Who may not be able to join:
- People who are currently taking part in another clinical trial involving an experimental drug or medical device
- People whose blood platelet count is below 100,000/μl (platelets are cells that help blood clot)
- People whose brain scans show a tumour (except a small, non-inflamed meningioma under 3 cm), any active bleeding in the brain, or an abnormal tangle of blood vessels (arteriovenous malformation)
- People whose brain scans show significant shifting of brain structures to one side (midline shift greater than 3 mm) or signs of swelling pressing on the opposite side of the brain
- People with evidence of a tear in the internal carotid artery that is blocking blood flow, or a tear in the main artery leaving the heart (aorta)
- People who have a previously placed stent inside the brain in the same area as the blockage, which could make the clot-removal procedure unsafe
- People who have blockages in more than one separate brain artery at the same time (for example, blockages in both sides of the brain, or in two different major arteries)
- People whose brain scans already show a clearly established area of dead brain tissue or swelling on standard CT imaging
- People whose brain scan score (CT ASPECTS) is 0, 1, or 2, indicating very extensive early brain damage
- People whose brain scans show that the area of severely damaged brain tissue is greater than 150 ml in volume
- People who had a stroke while already in hospital and whose symptoms were fluctuating, if they first presented to the hospital within 24 hours of when they were last known to be well (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Amrou Sarraj, MD, University Hospitals
Phone: 216-286-6458
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The distribution of the modified Rankin Scale score
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.